Mario Salvi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2526807/publications.pdf

Version: 2024-02-01

66 papers	5,434 citations	147801 31 h-index	138484 58 g-index
89 all docs	89 docs citations	89 times ranked	2617 citing authors

#	Article	IF	Citations
1	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment. Ophthalmology, 2022, 129, 438-449.	5.2	64
2	Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. Thyroid, 2021, 31, 821-828.	4.5	24
3	Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. Thyroid, 2021, 31, 280-287.	4.5	5
4	Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2021, 12, 790246.	3.5	10
5	SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes and Endocrinology,the, 2020, 8, 739-741.	11.4	225
6	Teprotumumab for the Treatment of Active Thyroid Eye Disease. New England Journal of Medicine, 2020, 382, 341-352.	27.0	375
7	Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. Thyroid, 2019, 29, 1828-1833.	4.5	22
8	Predictive score for the development or progression of Gravesâ€™ orbitopathy in patients with newly diagnosed Gravesâ€™ hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	3.7	59
9	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	11.4	128
10	Pretibial Myxedema. , 2018, , 707-710.		0
11	Tocilizumab for thyroid eye disease. The Cochrane Library, 2018, 11, CD012984.	2.8	15
12	Combined immunosuppressants and less steroids in active gravesâ€™ orbitopathy?. Clinical Endocrinology, 2018, 90, 525-527.	2.4	3
13	Step-down steroid-sparing therapy in active thyroid eyeÂdisease. Nature Reviews Endocrinology, 2018, 14, 634-635.	9.6	4
14	Combining micro-RNA and protein sequencing to detect robust biomarkers for Gravesâ€™ disease and orbitopathy. Scientific Reports, 2018, 8, 8386.	3.3	33
15	Gravesâ€™ Orbitopathy. , 2018, , 711-718.		0
16	Hyperthyroidism in Gravesâ€™ Disease. , 2018, , 702-706.		1
17	Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine, 2017, 376, 1748-1761.	27.0	480
18	MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Gravesâ€™ orbitopathy â€“ lessons from randomized control trials. European Journal of Endocrinology, 2017, 176, R101-R109.	3.7	83

#	Article	IF	Citations
19	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
20	THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2016, 175, R117-R133.	3.7	31
21	Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 422-431.	3.6	291
22	PREGO (presentation of Gravesâ€™ orbitopathy) study: changes in referral patterns to European Group On Gravesâ€™ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	3.9	92
23	Statins May Increase the Risk of Liver Dysfunction in Patients Treated With Steroids for Active Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1731-1737.	3.6	12
24	B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases. Thyroid, 2015, 25, 1043-1049.	4.5	24
25	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. Thyroid, 2015, 25, 1181-1184.	4.5	8
26	Management of Severe Thyroid Eye Disease and Use of Biological Agents. , 2015, , 89-97.		0
27	Future Therapy for Gravesâ€™ Disease and Ophthalmopathy. , 2015, , 317-336.		0
28	Immunotherapy for Gravesâ€™ ophthalmopathy. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 409-414.	2.3	32
29	The therapeutic outcome of intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology, 2014, 170, 55-61.	3.7	39
30	Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic Neuropathy. Thyroid, 2014, 24, 897-905.	4.5	94
31	A Quantitative Method for Assessing the Degree of Axial Proptosis in Relation to Orbital Tissue Involvement in Graves' Orbitopathy. Ophthalmology, 2013, 120, 1092-1098.	5.2	14
32	Potential Utility of Rituximab for Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4291-4299.	3.6	81
33	Treatment of Pretibial Myxedema with Dexamethazone Injected Subcutaneously by Mesotherapy Needles. Thyroid, 2013, 23, 626-632.	4.5	20
34	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. JAMA Ophthalmology, 2012, 130, 122.	2.4	75
35	Serum BAFF Concentrations in Patients with Graves' Disease and Orbitopathy before and after Immunosuppressive Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E755-E759.	3.6	39
36	Cytokines (interferon-Î³ and tumor necrosis factorâ€“Î±)-induced nuclear factorâ€“ÎºB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism: Clinical and Experimental, 2011, 60, 277-283.	3.4	34

#	Article	IF	Citations
37	B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 99-111.	0.5	0
38	Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology, 2010, 161, 436-443.	2.6	49
39	Corneal Involvement in Graves' Orbitopathy: An In Vivo Confocal Study. , 2010, 51, 4574.		85
40	Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?. Orbit, 2009, 28, 251-255.	0.8	15
41	Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates. Clinical Immunology, 2009, 131, 360-365.	3.2	58
42	Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?. Orbit, 2009, 28, 251-255.	0.8	22
43	Rituximab in the treatment of thyroid eye disease: science fiction?. Orbit, 2009, 28, 251-5.	0.8	10
44	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	3.7	611
45	DeclaraciÃ³n de consenso del Grupo europeo sobre la orbitopatÃa de Graves (EUGOGO) sobre el tratamiento de la orbitopatÃa de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0
46	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
47	Treatment of Gravesâ€™ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 2007, 156, 33-40.	3.7	230
48	Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology, 2006, 154, 511-517.	3.7	131
49	Onset of Autoimmune Hepatitis During Intravenous Steroid Therapy for Thyroid-Associated Ophthalmopathy in a Patient with Hashimoto's Thyroiditis: Case Report. Thyroid, 2004, 14, 631-634.	4.5	55
50	Recombinant interferon Î± (rIFN-Î±) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clinical Endocrinology, 1999, 50, 95-100.	2.4	11
51	Role of the Eye Muscles in Thyroid Eye Disease: Identification of the Principal Autoantigens. Thyroid, 1998, 8, 553-556.	4.5	38
52	Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clinical Endocrinology, 1997, 47, 357-361.	2.4	39
53	Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. American Journal of Medicine, 1996, 101, 482-487.	1.5	170
54	Upper Eyelid Retraction in the Absence of Other Evidence for Progressive Ophthalmopathy is Associated with Eye Muscle Autoantibodies. Clinical Immunology and Immunopathology, 1995, 74, 44-50.	2.0	15

#	Article	IF	Citations
55	Circadian thyrotropin variations are preserved in normal pregnant women. European Journal of Endocrinology, 1995, 133, 71-74.	3.7	7
56	Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. European Journal of Endocrinology, 1994, 131, 113-119.	3.7	37
57	Detection of anti-pituitary autoantibodies by immunoblotting. Journal of Immunological Methods, 1993, 162, 31-40.	1.4	71
58	Thyroid-associated ophthalmopathy â€" a model for the association of organ-specific autoimmune disorders. Trends in Immunology, 1991, 12, 150-153.	7.5	74
59	Immunologically Mediated Cytotoxicity Against Human Eye Muscle and Thyroid Cells in Euthyroid and Thyrotoxic Gravesâ€™ Ophthalmopathy. Autoimmunity, 1991, 9, 293-300.	2.6	2
60	Prevalence of Antibodies Reactive with a 64 kDa Eye Muscle Membrane Antigen in Thyroid-Associated Ophthalmopathy. Thyroid, 1991, 1, 207-213.	4.5	48
61	A Thyroid Cytotoxic Antibody That Cross-reacts With an Eye Muscle Cell Surface Antigen May Be the Cause of Thyroid-Associated Ophthalmopathy*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 565-570.	3.6	73
62	Basal and glucose- and arginine-stimulated serum concentrations of insulin, C-peptide, and glucagon in hyperthyroid patients. Metabolism: Clinical and Experimental, 1986, 35, 337-342.	3.4	16
63	Goiter Size and Thyroid Function in an Endemic Goiter Area in Northern Italy *. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 558-563.	3.6	31
64	Human foetal prolactin but not thyrotropin secretion is decreased by bromocriptine. European Journal of Endocrinology, 1986, 112, 35-42.	3.7	7
65	Inhibition of foetal growth hormone (GH) and thyrotrophin (TSH) secretion after maternal administration of somatostatin. European Journal of Endocrinology, 1984, 106, 393-399.	3.7	15
66	Tocilizumab for thyroid eye disease. The Cochrane Library, 0, , .	2.8	0